samedan logo

 
 
spacer
home > pmps > summer 2017 > intriguing injections
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Intriguing Injections

PMPS: What are pre-filled syringes (PFSs) and what are they most commonly used for?

Kevin O’Brien: PFSs, by design, are self-administering drug delivery systems. This home-friendly device offers significant benefits to patients, healthcare professionals and manufacturers compared to traditional ‘vial and syringe’ methods. The majority of medications delivered by PFSs are used for chronic diseases, such as diabetes, rheumatoid arthritis and multiple sclerosis. The healthcare industry is increasingly seeing price pressures that generate a growing need for innovative ways to reduce expenses. Thus, these systems are a cost-saving option.

What advantages do patients receive from using a PFS as opposed to other drug delivery systems?

Ultimately, they receive convenience, bettering their quality of life. PFSs allow medication to be safely administered at home, eliminating travel time and doctor office visits. PFSs are becoming of greater interest among many pharmaceutical manufacturers due to their ease-ofuse, which means that these systems can be offered at a premium price. Overall, a PFS makes self-injection easier, and dosing is much more accurate than the traditional vial and syringe, which, in turn, improves patient compliance and outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer
Kevin O’Brien is Vice President at Siegfried. Before joining the company, he held General Manager positions at Horizon Medical, Surgical Technologies and Pharmacia. Kevin has worked in the medical device and pharma industry since 1986. His background includes both Operations Management and Business Development.
spacer
Kevin O’Brien
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine

First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed with BioNTech to use Novartis manufacturing plant in Stein, Switzerland, to support production of mRNA COVID-19 vaccine Production to commence in the second quarter for estimated delivery commencing in the third quarter 2021
More info >>

White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement